Melbourne biotech startup venture CNSDose has closed a seed investment of nearly $1 million from two angel investors. CNSDose seeks to refine how antidepressants are prescribed to individual patients through the use of a genomic test.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
